SUNPHARMA
SUNPHARMA · NSE
₹1,884.9
-0.79% (-₹15.1)
Prev. close
₹1,900
Volume
19,16,054
Delivery %
57.5%
As of
20 Nov 2026
Price history
Nooresh Merani · Independent · 24 Oct 2024, 09:26 IST
“Bearish on Sun Pharma with a target of ₹1,700 and a stop loss at ₹1,880 for a short-term trading horizon.”
Entry ≈ ₹1,856.8 (first trade after call)Target ₹1,700 (-8.4%)Stop ₹1,880 (+1.2%)R:R ~6.8:1Stopped out · 28 Oct 2024
Analyst sentiment
Analysts lean bullish
7 analyst stances · last 90 days · one per analyst
Trackable
7 · 7 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Nuvama retains its 'buy' rating on Sun Pharma, with a reduced target price of ₹2,320, indicating a 30.5% upside from its…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Sun Pharma | PENDING | ||||
| “HSBC maintains a 'buy' recommendation on Sun Pharma, reducing its target price to ₹2,050, implying a 15.3% upside. The f…” | HSBC AnalysisHSBC | Sun Pharma | PENDING | ||||
| “UBS has a 'buy' rating on Sun Pharma with a target price of ₹2,200, suggesting a 23.8% upside. The company reported stro…” | UBS AnalysisUBS | Sun Pharma | PENDING | ||||
| “Nomura holds a 'buy' rating on Sun Pharma with a target price of ₹2,260, implying a 27% upside. While Q2 was mixed with …” | Nomura AnalysisNomura Global Markets Research | Sun Pharma | PENDING | ||||
| “Maintained a 'Buy' rating on Sun Pharmaceutical Industries with an unchanged target price of ₹2,300, implying a potentia…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Sun Pharmaceutical Industries | PENDING | ||||
| “Bullish on Sun Pharma, recommending a buy at ₹1778 with a target of ₹1985 and a stop loss at ₹1690. The stock shows stre…” | Sumeet BagadiaChoice Equity Broking | Sun Pharma | PENDING | ||||
| “Recommends buying Sun Pharmaceutical Industries futures in the ₹1,760-₹1,770 range, targeting ₹1,840-₹1,880 with a stop-…” | Jay ThakkarICICI Securities | Sun Pharmaceutical Industries | HIT | ||||
| “Bullish on Sun Pharma for the next six months, recommending a buy between ₹1,930 and ₹1,970 with a target of ₹2,250 and …” | Pabitro MukherjeeBajaj Broking | Sun Pharmaceutical Industries Ltd | MISS | ||||
| “Recommends buying Sun Pharmaceutical Industries in the ₹1700-1720 range, targeting ₹1780, with a stop loss at ₹1670. Thi…” | Ganesh DongreAnand Rathi | Sun Pharmaceutical Industries | HIT | ||||
| “Bullish on Sun Pharma for the short term (1-2 weeks), with a target price of ₹1,930 and a stop loss at ₹1,745. The pharm…” | Ajit MishraReligare Broking | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Recommends buying Sun Pharmaceutical Industries with a target price of ₹1875. The call implies a bullish outlook on the …” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Sun Pharmaceutical Industries | HIT | ||||
| “Emkay Global Financial recommends buying Sun Pharma with a target price of ₹2,000. The call is based on the company's st…” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Sun Pharmaceutical Industries Ltd. | HIT | ||||
| “Prabhudas Lilladher Capital maintained a 'Buy' rating on Sun Pharma with a target price of ₹1,875, citing strong visibil…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Sun Pharmaceutical Industries | HIT | ||||
| “Emkay retained a 'BUY' rating on Sun Pharma with a target price of ₹2,000, reflecting a positive outlook on the company'…” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Sun Pharmaceutical Industries | HIT | ||||
| “Recommends buying Sun Pharma at ₹1699, targeting ₹1818 with a stop loss at ₹1640. The stock shows signs of recovery afte…” | Sumeet BagadiaChoice Equity Broking | Sun Pharmaceutical Industries Ltd. | HIT | ||||
| “Motilal Oswal recommends buying Sun Pharma with a target price of ₹1960. The call is based on the company's strong marke…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Sun Pharmaceutical Industries Ltd. | HIT | ||||
| “Bearish on Sun Pharma, downgrading to 'underperform' from 'neutral' and lowering the target price to ₹1,570 from ₹1,730.…” | Private Bank Trader AnalysisPrivate Bank Trader | Sun Pharmaceutical Industries Ltd. | HIT | ||||
| “Bullish on Sun Pharma, recommending a buy at ₹1641 with a target of ₹1760 and a stop loss at ₹1585. The stock is stabili…” | Sumeet BagadiaChoice Equity Broking | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Recommends selling Sun Pharma today at ₹1594, targeting ₹1560, with a stop loss at ₹1620.” | Vaishali ParekhPrabhudas Lilladher | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Retained a 'Buy' rating on Sun Pharma, despite lowering the target price to Rs 1,960 from Rs 2,000. The brokerage cites …” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Sun Pharmaceutical Industries Ltd. | HIT | ||||
| “Upgraded Sun Pharma to 'Add' from 'Reduce' and raised the target price to Rs 1,830 from Rs 1,770. While FY26 margins may…” | Avendus AnalysisAvendus | Sun Pharmaceutical Industries Ltd. | HIT | ||||
| “Recommends buying Sun Pharma for 2-3 weeks, targeting ₹1,800 with a stop loss at ₹1,650. The stock has formed a robust b…” | Jigar S. PatelAnand Rathi Share and Stock Brokers | Sun Pharmaceutical Industries | MISS | ||||
| “Recommends buying Sun Pharmaceutical Industries at ₹1,699, targeting ₹1,850 with a stop loss at ₹1,620. The stock is in …” | Sumeet BagadiaChoice Equity Broking | Sun Pharmaceutical Industries | MISS | ||||
| “Bullish on Sun Pharmaceutical for the short term, recommending long positions in the ₹1,670–1,650 range with a target of…” | Jigar S. PatelAnand Rathi Share and Stock Brokers | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Bullish on Sun Pharma, recommending a buy with a target of ₹1710 and a stop loss at ₹1650.” | Kunal BothraIndependent | Sun Pharmaceutical Industries Ltd. | HIT | ||||
| “Recommends buying Sun Pharmaceutical Industries for the short term (2-3 weeks), targeting ₹1,840 with a stop loss below …” | Jigar S. PatelAnand Rathi Share and Stock Brokers | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Recommends selling Sun Pharma today at ₹1649, targeting ₹1600, with a stop loss at ₹1660.” | Vaishali ParekhPrabhudas Lilladher | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Recommends buying Sun Pharmaceutical Industries at ₹1,715, targeting ₹1,820 with a stop loss at ₹1,655, over a 1-week ti…” | Nagaraj ShettiHDFC Securities | Sun Pharmaceutical Industries | PENDING | ||||
| “Recommends accumulating Sun Pharmaceutical Industries with a target of ₹1811. The call implies a bullish outlook on the …” | Deven ChokseyIndependent | Sun Pharmaceutical Industries | HIT | ||||
| “JM Financial maintains a 'Buy' rating on Sun Pharmaceutical Industries with a revised target price of Rs 2,025 for a one…” | JM Financial AnalysisJM Financial Institutional Securities | Sun Pharmaceutical Industries | MISS | ||||
| “Motilal Oswal recommends buying Sun Pharma with a target price of ₹2,000. The call implies a bullish outlook on the stoc…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Prabhudas Lilladher recommends buying Sun Pharmaceutical Industries with a target price of ₹2,000. This call suggests a …” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Sun Pharmaceutical Industries | MISS | ||||
| “Bullish on Sun Pharma, retaining a 'Buy' rating with a target price of ₹2,250 for March 2026. Q4FY25 EBITDA was in line …” | Shashank KrishnakumarEmkay Global Financial Services | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Bullish on Sun Pharmaceutical Industries, recommending a buy with a target price of ₹1,950 and a stop loss at ₹1,785. Th…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Sun Pharmaceutical Industries | MISS | ||||
| “Recommends buying Sun Pharma at ₹1785 with a stop loss at ₹1740 and a target price of ₹1850. This call is for Monday, Ap…” | Ganesh DongreAnand Rathi | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Recommends buying Sun Pharma with a target of ₹1787 and a stop loss at ₹1727, based on technical analysis for a short-te…” | Jatin GediaSharekhan by BNP Paribas | Sun Pharmaceutical Industries Ltd. | PENDING | ||||
| “Bearish on Sun Pharmaceutical Industries, recommending a sell below ₹1,685 with a target of ₹1,630 and a stop loss at ₹1…” | Rupak DeLKP Securities | Sun Pharmaceutical Industries | PENDING | ||||
| “Emkay Global Financial recommends buying Sun Pharma with a target price of ₹2,400.” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Maintains a Buy rating on Sun Pharma with a target price of ₹2,145. The company is expected to post 22.6% YoY sales grow…” | Centrum Broking AnalysisCentrum Broking | Sun Pharmaceutical Industries Ltd | MISS | ||||
| “Bullish on Sun Pharmaceutical, reiterating confidence in it as a 'Star' stock and core holding over a 12-24 month horizo…” | Macquarie AnalysisMacquarie Capital Securities | Sun Pharmaceutical Industries Ltd. | PENDING | ||||
| “Bullish on Sun Pharmaceutical Industries for the short term, recommending a buy with a target of ₹1,750 and a stop-loss …” | Riyank AroraMehta Equities | Sun Pharmaceutical Industries Ltd | HIT | ||||
| “Sun Pharma has extended its bounce-back rally for the second consecutive week, forming a 'morning star' reversal pattern…” | Rajesh PalviyaAxis Securities | Sun Pharmaceutical Industries Ltd | HIT | ||||
| “Upgraded Sun Pharma to 'Buy' from 'Hold' with a revised target price of ₹1,895, up from ₹1,840. The upgrade is based on …” | ICICI Securities AnalysisICICI Securities | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “ICICI Securities recommends buying Sun Pharmaceutical Industries with a target price of ₹1895. The call is based on the …” | ICICI Securities AnalysisICICI Securities | Sun Pharmaceutical Industries | MISS | ||||
| “Recommends buying Sun Pharmaceutical Industries at ₹1615, targeting ₹1650 with a stop loss at ₹1585. A notable bullish r…” | Ganesh DongreAnand Rathi | Sun Pharmaceutical Industries | PENDING | ||||
| “Maintains a 'buy' rating on Sun Pharmaceutical Industries with a revised target price of ₹2,000, indicating a 24% upside…” | HSBC AnalysisHSBC | Sun Pharmaceutical Industries | MISS | ||||
| “JM Financial has a 'Buy' call on Sun Pharmaceutical Industries with a 12-month target price of Rs 2,115, up from the cur…” | JM Financial AnalysisJM Financial Institutional Securities | Sun Pharmaceutical Industries | MISS | ||||
| “Recommends selling Sun Pharmaceutical Industries Ltd at ₹1,700, targeting ₹1,670, with a stop loss at ₹1,725.” | Vaishali ParekhPrabhudas Lilladher | Sun Pharmaceutical Industries Ltd | MISS | ||||
| “Bearish on Sun Pharmaceutical Industries Ltd; recommends selling below ₹1,699 with a stop loss at ₹1,730 and a target of…” | Raja VenkatramanNeoTrader | Sun Pharmaceutical Industries Limited | MISS | ||||
| “Bearish on Sun Pharmaceutical Industries, recommending to sell below ₹1,699 with a stop loss at ₹1,730 and a target of ₹…” | Raja VenkatramanNeoTrader | Sun Pharmaceutical Industries Limited | HIT | ||||
| “Choice Institutional Equities recommends buying Sun Pharmaceutical Industries with a target price of ₹2,200, based on a …” | Choice Institutional Equities AnalysisChoice Institutional Equities | Sun Pharmaceutical Industries | MISS | ||||
| “Maintained a 'Buy' rating on Sun Pharma, raising the target price to ₹2,265 from ₹2,260. The company showed strong perfo…” | Jefferies AnalysisJefferies | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Maintained a 'Sell' rating on Sun Pharma, revising the target price to ₹1,625 from ₹1,650. The firm believes current val…” | Goldman Sachs AnalysisGoldman Sachs Group Inc. | Sun Pharmaceutical Industries Ltd. | HIT | ||||
| “Bullish on Sun Pharma, recommending a buy at ₹1833.60 with a stop loss at ₹1769 for a target price of ₹1962. The stock s…” | Sumeet BagadiaChoice Equity Broking | Sun Pharmaceutical Industries Ltd | PENDING | ||||
| “Emkay Global Financial recommends buying Sun Pharma with a target price of ₹2,400. The call implies a bullish outlook on…” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Sun Pharmaceutical Industries Ltd. | MISS | ||||
| “Recommends buying Sun Pharmaceuticals shares at ₹1,767 with a target price of ₹1,800 and a stop loss of ₹1,745 for today…” | Vaishali ParekhPrabhudas Lilladher | Sun Pharmaceutical Industries Ltd. | HIT | ||||
| “Bullish on Sun Pharma, recommending a buy at ₹1,770 with a target of ₹1,820-1,835 and a stop loss at ₹1,723. The stock h…” | Ankush BajajIndependent | Sun Pharmaceutical Industries Ltd. | HIT | ||||
| “Bullish on Sun Pharma, recommending a buy at ₹1,770 with a target of ₹1,820-1,835 and a stop loss at ₹1,723. The stock h…” | Ankush BajajIndependent | Sun Pharmaceutical Industries Ltd. | HIT | ||||
| “JM Financial maintains a 'buy' call on Sun Pharmaceutical Industries with a target price of Rs 2094, expecting the stock…” | JM Financial AnalysisJM Financial Institutional Securities | Sun Pharmaceutical Industries | MISS | ||||
| “Prabhudas Lilladher recommends buying Sun Pharmaceutical Industries with a target price of ₹2,100. The call implies a bu…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Sun Pharmaceutical Industries | PENDING | ||||
| “Maintains a buy rating on Sun Pharma, increasing the target price to Rs 2,150 from Rs 2,000. Q2 saw continued growth mom…” | Jefferies AnalysisJefferies | Sun Pharmaceutical Industries Ltd. | PENDING | ||||
| “Bearish on Sun Pharma with a target of ₹1,700 and a stop loss at ₹1,880 for a short-term trading horizon.” | Nooresh MeraniIndependent | Sun Pharmaceutical Industries Ltd. | MISS | ||||
“Bearish on Sun Pharma with a target of ₹1,700 and a stop loss at ₹1,880 for a short-term trading horizon.” How this call is judged A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open. No entry price is stated, so the call starts at the first close after it was published. Target ₹1,700, stop ₹1,880, as stated. No time frame is stated, so it is tracked until a close reaches ₹1,700 or ₹1,880: there is no fixed window. The stop ₹1,880 was reached on a close before the target ₹1,700. Miss. The grader's working: R4 TARGET_CALL: entered ₹1860.4 on 2024-10-25 (next trading session's close); stop ₹1880 breached at close ₹1902.9 on 2024-10-28. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open. (28 Oct 2024) | |||||||
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on pharma; Sun Pharma and Aurobindo Pharma are key large-cap plays. Sun Pharma remains a key stock to watch afte…” | Rahul ShahMotilal Oswal Financial Services | Sun Pharmaceutical Industries Ltd. | — | |
| “Emphatically bullish on the Indian pharma sector, believing it is at the start of a multi-decade run and on the cusp of …” | Sudip BandyopadhyayIndependent | Sun Pharma | — | |
| “Regarding Sun Pharma's recent acquisition, Sandip Sabharwal notes a positive initial market reaction and strategic fit, …” | Sandip Sabharwalasksandipsabharwal.com | Sun Pharma | — | |
| “Devarsh Vakil of HDFC Securities holds a positive view on Sun Pharma, highlighting its strategy of deploying strong cash…” | Devarsh VakilHDFC Securities | Sun Pharma | — | |
| “Amit Khurana views Sun Pharma's recent acquisition as strategically sound and directionally correct for long-term growth…” | Amit KhuranaDolat Capital | Sun Pharma | — | |
| “Sudip Bandyopadhyay identifies genuine earnings risk for Indian pharma companies with branded drug exposure in the US ma…” | Sudip BandyopadhyayIndependent | Sun Pharma | — | |
| “Amnish Aggarwal is bullish on the pharma sector, noting its recent comeback driven by good numbers and attractive valuat…” | Amnish AggarwalPrabhudas Lilladher Capital | Sun Pharma | — | |
| “Bullish on Sun Pharma, which has broken a year-long downtrend and a descending triangle pattern, supported by increased …” | ETMarkets AnalysisETMarkets.com | Sun Pharmaceutical Industries Ltd. | — | |
| “Elara Securities upgraded its estimate for Sun Pharma by 5% to ₹1,968, reflecting an improved margin outlook and sustain…” | Elara Capital AnalysisElara Capital | Sun Pharmaceutical Industries | — | |
| “Analysts have maintained 'BUY' on Sun Pharma with an upside of 11-18% to Friday's closing of ₹1,692.8, expecting recent …” | ET Intelligence Group AnalysisET Intelligence Group | Sun Pharmaceutical Industries | — | |
| “Maintains a 'HOLD' rating on Sun Pharma with a target price of ₹1,800, implying over 5% downside from current levels. Th…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Sun Pharmaceutical Industries Ltd | — | |
| “Maintained a 'Hold' rating on Sun Pharma with a target price of Rs 1,830. The brokerage expects FY26 to be investment-he…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Sun Pharmaceutical Industries Ltd. | — | |
| “Bearish on Sun Pharmaceutical Futures for the short-term, recommending a sell in the ₹1,650-₹1,640 range with a target o…” | Jay ThakkarICICI Securities | Sun Pharmaceutical Industries Ltd | — | |
| “Neutral on Sun Pharma, retaining a 'Hold' rating with an unchanged target price of ₹1,830. While gross margin performanc…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Sun Pharmaceutical Industries Ltd. | — | |
| “Neutral on Sun Pharma, downgrading its rating to 'Add' and cutting the target price to ₹1,825 from ₹2,200 earlier. The f…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Sun Pharmaceutical Industries Ltd. | — | |
| “Recommends buying Sun Pharma in the range of ₹1725-1745, setting a stop loss at ₹1675 and targeting a price of ₹1830. Th…” | Ganesh DongreAnand Rathi | Sun Pharmaceutical Industries Ltd. | — | |
| “Bullish on Sun Pharma, which has consolidated between ₹1600-₹1800 and is now sustaining above ₹1800 (currently around ₹1…” | Aamar Deo SinghAngel One | Sun Pharmaceutical Industries Ltd. | — | |
| “Motilal Oswal sees over 20% upside in Sun Pharma, indicating a bullish outlook on the stock's performance over the next …” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Sun Pharmaceutical Industries Ltd. | — | |
| “Bullish on Sun Pharmaceutical Industries Ltd, recommending a buy in the range of ₹1,720–1,760 with a profit goal of ₹1,8…” | Marketsmith India AnalysisMarketsmith India | Sun Pharmaceutical Industries Ltd | — | |
| “Recommends buying Sun Pharmaceutical Industries Ltd. in the range of ₹1,720–₹1,760, targeting a profit goal of ₹1,890 wi…” | Marketsmith India AnalysisMarketsmith India | Sun Pharmaceutical Industries Ltd. | — | |
| “Maintained a 'Hold' rating on Sun Pharma, raising the target price to ₹1,830 from ₹1,815. The EBITDA margin improved due…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Sun Pharmaceutical Industries Ltd. | — | |
| “The consensus recommendation from 38 analysts for Sun Pharma is a 'Buy', with an average target price of ₹2,047, indicat…” | Trendlyne AnalysisTrendlyne | Sun Pharmaceutical Industries Ltd. | — |
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Dilip Shantilal Shanghvi
Headquarters
Mumbai
Employees
47,000
Website
sunpharma.comExchange
View on NSE ↗Key stats
Market cap
₹4.30 L Cr
P/E ratio (TTM)
39.3
Dividend yield
0.90%
EPS (TTM)
₹45.70
Beta (1Y · daily vs NIFTY 50)
0.43
Beta (5Y · monthly vs NIFTY 50)
0.85
Shares float
83.05 Cr
EPS · quarter ended Sept 2026
₹8.30
Upcoming earnings
28 Jan 2027
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹33,498.14 Cr | ₹38,654.49 Cr | ₹43,885.68 Cr | ₹48,496.85 Cr | ₹52,578.44 Cr | ₹58,462.04 Cr | |
EBITDA | ₹5,020.75 Cr | ₹6,752.41 Cr | ₹12,109.86 Cr | ₹13,883.00 Cr | ₹16,558.88 Cr | ₹18,395.64 Cr |
| ₹2,903.82 Cr | ₹3,272.73 Cr | ₹8,473.58 Cr | ₹9,576.38 Cr | ₹10,929.04 Cr | ₹11,479.42 Cr | |
Diluted EPS | ₹12.1 | ₹13.6 | ₹35.3 | ₹39.9 | ₹45.6 | ₹47.8 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹67,666.73 Cr | ₹69,807.77 Cr | ₹80,743.59 Cr | ₹85,462.88 Cr | ₹92,100.58 Cr | ₹1.09 L Cr | |
| ₹3,868.58 Cr | ₹1,290.30 Cr | ₹6,885.87 Cr | ₹3,273.67 Cr | ₹2,362.19 Cr | ₹4,627.32 Cr | |
Stockholders' equity | ₹46,462.78 Cr | ₹48,011.22 Cr | ₹55,995.38 Cr | ₹63,666.75 Cr | ₹72,218.02 Cr | ₹83,570.09 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹6,170.37 Cr | ₹8,984.54 Cr | ₹4,959.33 Cr | ₹12,134.98 Cr | ₹14,072.09 Cr | ₹12,419.18 Cr | |
Investing cash flow | ₹536.22 Cr | ₹-5,724.74 Cr | ₹-7,943.68 Cr | ₹-690.20 Cr | ₹-5,306.16 Cr | ₹-11,344.05 Cr |
| ₹-5,980.48 Cr | ₹-5,193.46 Cr | ₹2,376.07 Cr | ₹-6,710.16 Cr | ₹-7,905.82 Cr | ₹-2,512.55 Cr | |
Capital expenditure | ₹-1,170.13 Cr | ₹-1,495.04 Cr | ₹-2,085.58 Cr | ₹-2,201.81 Cr | ₹-2,128.58 Cr | ₹-3,609.37 Cr |
End cash position | ₹6,273.03 Cr | ₹4,508.25 Cr | ₹4,623.73 Cr | ₹9,285.65 Cr | ₹10,268.77 Cr | ₹9,770.51 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 54.48% |
| Public | 45.52% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Lupin Limited | ₹92,244.53 Cr | ₹2,008.6 | 16.7 | 4.11 | 23.8% | 0.29 | +23.9% | +0.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.